Regencell Bioscience Holdings Limited
RGC
Rank in Stocks
#3353
Regencell Bioscience Holdings Limited is a biotechnology firm specializing in... Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.
Share Price
$10.57
Market Cap
$5.24B
Change (1 day)
5.20%
Change (1 year)
-37.66%
Country
HK
Trade Regencell Bioscience Holdings Limited (RGC)
Category
Healthcare
P/B ratio for Regencell Bioscience Holdings Limited (RGC)
P/B ratio as of October 2026 TTM: 300.54
According to Regencell Bioscience Holdings Limited latest financial reports and stock price the company's current price-to-book ratio (TTM) is 300.54. At the end of 2024 the company had a P/B ratio of 5.08.
P/B ratio history for Regencell Bioscience Holdings Limited from 2019 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 300.54 | -82.66% |
| 2025 | 1.73K | 34,010.49% |
| 2024 | 5.08 | -79.61% |
| 2023 | 24.92 | -5.54% |
| 2022 | 26.38 | -179.45% |
| 2021 | -33.21 | -33.69% |
| 2020 | -50.08 | -30.65% |
| 2019 | -72.20 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | -98.32% |
IN
|
